Methods for diagnosing cancer based on DNA methylation status in NBL2
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Apr 19, 2007
app pub date -
Oct 19, 2005
filing date -
Oct 19, 2005
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The present invention relates to methods for diagnostic or prognostic assay for cancer based on analysis of altered methylation status at specific CpG dinucleotide sequences within the epigenetic marker, NBL2. The methods of the invention comprise determining the methylation status of a subregion of genomic CpG dinucleotide sequences within the DNA repeat, NBL2, in a sample of a subject and comparing the methylation status of the genomic CpG dinucleotide sequences in the sample to the methylation status of the genomic CpG dinucleotide sequences in a reference, wherein a difference in the methylation status of the genomic CpG dinucleotide sequences in the sample as compared to the reference indicates an association of the subject with cancer or cancer progression. The invention further relates to genomic DNA sequences that exhibit altered CpG methylation status in disease state as compared to normal state. The invention also provides nucleic acids, nucleic acid arrays and kits useful for practicing the methods of the present invention.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully